Ipragliflozin in combination with metformin for the treatment of Japanese patients with type 2 diabetes: ILLUMINATE, a randomized, double-blind, placebo-controlled study

This multicenter, double-blind, placebo-controlled study examined the efficacy and safety of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with metformin in Japanese patients with type 2 diabetes mellitus (T2DM). Patients were randomized in a 2: 1 ratio to 50 mg ipraglif...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diabetes Obes Metab
Hlavní autoři: Kashiwagi, A, Kazuta, K, Goto, K, Yoshida, S, Ueyama, E, Utsuno, A
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Ltd 2015
Témata:
Research Letters
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342773/
https://ncbi.nlm.nih.gov/pubmed/24919820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/dom.12331
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky